Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Бактериофаги в лечении инфекций нижних мочевыводящих путей
Бактериофаги в лечении инфекций нижних мочевыводящих путей
Васильев А.О., Зайцев А.В., Калинина Н.А. и др. Бактериофаги в лечении инфекций нижних мочевыводящих путей. Consilium Medicum. 2019; 21 (7): 38–41. DOI: 10.26442/20751753.2019.7.190511
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Данная статья адресована врачам разных специальностей и посвящена истории бактериофагов, а также опыту применения их в клинической практике. Современные данные о медицинском использовании бактериофагов формируют представление о механизмах действия микроорганизмов, преимуществах и недостатках при сравнении с более распространенными методами антибактериального лечения и профилактики, возможностях практического применения. В эру антибиотикорезистентности поиск альтернативных препаратов наиболее остро волнует современное медицинское сообщество. Усовершенствование технологий по производству препаратов, содержащих бактериофаги, позволит делать их более специфичными к бактериям-возбудителям инфекций. Наличие различных форм препаратов, таких как свечи, гели, таблетки, растворы и другие, упрощает клиническое применение бактериофагов. Актуальная на сегодняшний день проблема биопленок в урологии может быть решена с помощью бактериофагов. Фаги, как и другие вирусы, обладают антигенными свойствами и содержат группоспецифические и типоспецифические антигены. Из-за высокой специфичности многие бактериофаги служат диагностическими инструментами для идентификации бактериальных культур. Незаслуженно забытые в середине прошлого столетия бактериофаги переживают «второе рождение». Всемирно нарастающий интерес к фаготерапии и фагопрофилактике способствует повсеместному проведению новых клинических исследований.
Ключевые слова: бактериофаги, антибиотикорезистентность, эффективность.
Ключевые слова: бактериофаги, антибиотикорезистентность, эффективность.
________________________________________________
The article is addressed to doctors of various specialties and devoted to the history of bacteriophages and the experience of their use in clinical practice. Mo-dern data on their medical use form our image of their mechanism of action, their potential application in clinical practice, their advantages and disadvantages in comparison with more common methods of antibacterial treatment and prophylaxis. Improving the technology for the production of preparations containing bacteriophages will make them more specific for bacteria that cause infections. Various forms of drugs, such as suppositories, gels, tablets, solutions, and ot-hers, simplifies the clinical use of bacteriophages. The current problem of biofilms in urology can be solved by using bacteriophages. Phages, like other viruses, have antigenic properties and contain group-specific and type-specific antigens. Due to their high specificity, many bacteriophages serve as diagnostic tools for identifying bacterial cultures. The bacteriophages undeservedly forgotten in the middle of the last century were again enabled to be useful. Worldwide growing interest in phagotherapy contributes to the widespread implementation of new clinical research.
Key words: bacteriophage, antibiotic resistance, efficiency.
Key words: bacteriophage, antibiotic resistance, efficiency.
Полный текст
Список литературы
1. Rubinstein E, Ronald AR. Toronto declaration to combat antimicrobial resistance. Proceedings of the Global Resistance Day, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada.
2. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
3. Chanishvili, A. A Literature Review of the Practical Application of Bacteriophages. New York City: Nova Science Publishers, 2012.
4. Каверин В.А. Открытая книга. Ч. III. М., 1956.
[Kaverin V.A. Open book. Part III. M., 1956 (in Russian).]
5. Martin, SA, Haren MT. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011; 29: 179–84.
6. Abrams P, Cardozo L, Fall M. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167–78.
7. Kupelian V, Wei JT, O’leary. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the boston area community health (BACH) survey. Arch Intern Med 2006; 166: 2381–7.
8. Cornu JN, Ahyai S, Bachmann A. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–96.
9. Schneidewind L, Kranz J, Schlager D. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. Cent Eur J Urol 2017; 70: 112–7.
10. Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway. J Hosp Infect 2005; 60: 40–5.
11. Gould CV, Umscheid CA, Agarwal RK et al. Guideline for prevention of catheter-associated urinary tract infections. Infect Control Hosp Epidemiol 2010; 31 (4): 319–26.
12. Поздеев О.К., Федорова Е.Р., Валеева Ю.В. Микробиология. Методическое пособие. Бактериофаги. Учебно-методическое пособие для студентов медицинских вузов. Казань, 2012.
[Pozdeev O.K., Fedorova E.R., Valeeva Iu.V. Microbiology. Toolkit. Bacteriophages. Uchebno-metodicheskoe posobie dlia studentov meditsinskikh vuzov. Kazan', 2012 (in Russian).]
13. Xu Y, Liu Y, Liu Y et al. Bacteriophage therapy against Enterobacteriaceae. Virol Sinica 2015; 30 (1): 11–8.
14. Leitner L, Sybesma W, Chanishvili N et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol 2017; 17 (1): 90.
15. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119: S20–28.
16. Leverentz B, Conway WS, Alavidze Z et al. Examination of bacteriophage as a biocontrol method for Salmonella on fresh-cut fruit: a model study. J Food Prot 2001; 64: 1116–21.
17. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotech 2010; 11: 28–47.
18. Atterbury RJ, Van Bergen MA, Ortiz F et al. Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 2007; 73: 4543–9.
19. Malik R, Chhibber S. Protection with bacteriophage KØ1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. J Microbiol Immunol Infect 2009; 42: 134–40.
20. Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162: 1021–7.
2. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
3. Chanishvili, A. A Literature Review of the Practical Application of Bacteriophages. New York City: Nova Science Publishers, 2012.
4. Каверин В.А. Открытая книга. Ч. III. М., 1956.
[Kaverin V.A. Open book. Part III. M., 1956 (in Russian).]
5. Martin, SA, Haren MT. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011; 29: 179–84.
6. Abrams P, Cardozo L, Fall M. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167–78.
7. Kupelian V, Wei JT, O’leary. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the boston area community health (BACH) survey. Arch Intern Med 2006; 166: 2381–7.
8. Cornu JN, Ahyai S, Bachmann A. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–96.
9. Schneidewind L, Kranz J, Schlager D. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. Cent Eur J Urol 2017; 70: 112–7.
10. Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway. J Hosp Infect 2005; 60: 40–5.
11. Gould CV, Umscheid CA, Agarwal RK et al. Guideline for prevention of catheter-associated urinary tract infections. Infect Control Hosp Epidemiol 2010; 31 (4): 319–26.
12. Поздеев О.К., Федорова Е.Р., Валеева Ю.В. Микробиология. Методическое пособие. Бактериофаги. Учебно-методическое пособие для студентов медицинских вузов. Казань, 2012.
[Pozdeev O.K., Fedorova E.R., Valeeva Iu.V. Microbiology. Toolkit. Bacteriophages. Uchebno-metodicheskoe posobie dlia studentov meditsinskikh vuzov. Kazan', 2012 (in Russian).]
13. Xu Y, Liu Y, Liu Y et al. Bacteriophage therapy against Enterobacteriaceae. Virol Sinica 2015; 30 (1): 11–8.
14. Leitner L, Sybesma W, Chanishvili N et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol 2017; 17 (1): 90.
15. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119: S20–28.
16. Leverentz B, Conway WS, Alavidze Z et al. Examination of bacteriophage as a biocontrol method for Salmonella on fresh-cut fruit: a model study. J Food Prot 2001; 64: 1116–21.
17. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotech 2010; 11: 28–47.
18. Atterbury RJ, Van Bergen MA, Ortiz F et al. Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 2007; 73: 4543–9.
19. Malik R, Chhibber S. Protection with bacteriophage KØ1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. J Microbiol Immunol Infect 2009; 42: 134–40.
20. Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162: 1021–7.
________________________________________________
2. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
3. Chanishvili, A. A Literature Review of the Practical Application of Bacteriophages. New York City: Nova Science Publishers, 2012.
4. Kaverin V.A. Open book. Part III. M., 1956 (in Russian).
5. Martin, SA, Haren MT. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011; 29: 179–84.
6. Abrams P, Cardozo L, Fall M. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167–78.
7. Kupelian V, Wei JT, O’leary. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the boston area community health (BACH) survey. Arch Intern Med 2006; 166: 2381–7.
8. Cornu JN, Ahyai S, Bachmann A. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–96.
9. Schneidewind L, Kranz J, Schlager D. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. Cent Eur J Urol 2017; 70: 112–7.
10. Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway. J Hosp Infect 2005; 60: 40–5.
11. Gould CV, Umscheid CA, Agarwal RK et al. Guideline for prevention of catheter-associated urinary tract infections. Infect Control Hosp Epidemiol 2010; 31 (4): 319–26.
12. Pozdeev O.K., Fedorova E.R., Valeeva Iu.V. Microbiology. Toolkit. Bacteriophages. Uchebno-metodicheskoe posobie dlia studentov meditsinskikh vuzov. Kazan', 2012 (in Russian).
13. Xu Y, Liu Y, Liu Y et al. Bacteriophage therapy against Enterobacteriaceae. Virol Sinica 2015; 30 (1): 11–8.
14. Leitner L, Sybesma W, Chanishvili N et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol 2017; 17 (1): 90.
15. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119: S20–28.
16. Leverentz B, Conway WS, Alavidze Z et al. Examination of bacteriophage as a biocontrol method for Salmonella on fresh-cut fruit: a model study. J Food Prot 2001; 64: 1116–21.
17. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotech 2010; 11: 28–47.
18. Atterbury RJ, Van Bergen MA, Ortiz F et al. Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 2007; 73: 4543–9.
19. Malik R, Chhibber S. Protection with bacteriophage KØ1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. J Microbiol Immunol Infect 2009; 42: 134–40.
20. Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162: 1021–7.
Авторы
А.О. Васильев, А.В. Зайцев, Н.А. Калинина*, А.А. Ширяев, Ю.А. Ким, Д.Ю. Пушкарь
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*kalininatalia06@gmail.com
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*kalininatalia06@gmail.com
________________________________________________
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*kalininatalia06@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.